Evidence map›Paper›PMID 37599312›Full record

ArticleJournal of the Egyptian National Cancer Institute2023

Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients.

Mahmoud El-Bendary, Khaled Farid, Mohammad Arafa, Wagdi Elkashef, Talaat Abdullah, Ahmed El-Mesery

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Egyptian National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mahmoud El-BendaryTropical Medicine and Hepatogastroenterology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, 35516, Dakahlyia, Egypt. mmelbendary@gmail.com.ORCID http://orcid.org/0000-0002-3751-5927
Khaled FaridTropical Medicine and Hepatogastroenterology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, 35516, Dakahlyia, Egypt.ORCID http://orcid.org/0000-0002-2116-3242
Mohammad ArafaPathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.ORCID http://orcid.org/0000-0001-6514-3545
Wagdi ElkashefPathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.ORCID http://orcid.org/0000-0003-2600-8003
Talaat AbdullahGastroenterology Surgery Center, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.ORCID http://orcid.org/0000-0002-0078-2028
Ahmed El-MeseryTropical Medicine and Hepatogastroenterology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, 35516, Dakahlyia, Egypt.ORCID http://orcid.org/0000-0002-3151-4106
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsBoth S100A4 and Glypican-3 have been known to be engaged in HCC development and progression. This study aimed to evaluate both S100A4 and GPC3 expression in HCC tissues as a prognostic markers.

methodsTissues from 70 patients of HCC in cirrhotic HCV patients were evaluated by immunohistochemistry using antibodies against SA100A4 and GPC3 and compared with tumor-adjacent tissue (controls). All cases were followed for 40 months.

resultsGPC3 was more expressed in HCC (79%) than S100A4 (21%). S100A4 was more significantly expressed in cases showing metastasis, microscopic vascular emboli, necrosis, and grade III tumors. There was no relationship between overall survival and both S100A4 and GPC3. The only significant independent predictor for recurrence was decompensation (OR 3.037), while metastasis was significantly predicted by S100A4 expression (OR 9.63) and necrosis (OR 8.33).

conclusionS100A4 might be used as a prognostic marker for HCC, while GPC3 is a reliable marker of HCC diagnosis.

Indexed as

Carcinoma, HepatocellularHepatitis CLiver NeoplasmsGlypicansHumansLiver CirrhosisNecrosisPrognosisS100 Calcium-Binding Protein A4GlypicansGPC3 protein, humanS100A4 protein, humanS100 Calcium-Binding Protein A4CirrhoticGlypican-3HCVHepatocellular carcinomaPrognosis, S100A4

Identifiers

PMID37599312
PMCPMC13313961
OpenAlexW4386010331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.